1. Home
  2. AKBA
  3. AKBA News

Latest Akebia Therapeutics Inc. (AKBA) News on February 23, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AKBA

GlobeNewswire

18 days ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia announces ‘multiple positive business updates’
AKBA

TipRanks

a month ago

Akebia announces ‘multiple positive business updates’

Akebia Therapeutics Announces Multiple Positive Business Updates
AKBA

PR Newswire

a month ago

Akebia Therapeutics Announces Multiple Positive Business Updates

New Strong Sell Stocks for January 3rd
AKBA

Zacks

2 months ago

New Strong Sell Stocks for January 3rd

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AKBA

PR Newswire

2 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

High Growth Tech Stocks To Watch In December 2024
AKBA

Simply Wall St.

2 months ago

High Growth Tech Stocks To Watch In December 2024

Investors in Akebia Therapeutics (NASDAQ:AKBA) have unfortunately lost 73% over the last five years
AKBA

Simply Wall St.

2 months ago

Investors in Akebia Therapeutics (NASDAQ:AKBA) have unfortunately lost 73% over the last five years

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
AKBA

PR Newswire

2 months ago

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

New Strong Sell Stocks for December 5th
AKBA

Zacks

3 months ago

New Strong Sell Stocks for December 5th

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AKBA

PR Newswire

3 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis
AKBA

PR Newswire

3 months ago

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

New Strong Sell Stocks for November 27th
AKBA

Zacks

3 months ago

New Strong Sell Stocks for November 27th

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
AKBA

PR Newswire

3 months ago

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease
AKBA

PR Newswire

3 months ago

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference
AKBA

PR Newswire

3 months ago

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50
AKBA

Simply Wall St.

3 months ago

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50

Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...
AKBA

GuruFocus.com

3 months ago

Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...

Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
AKBA

Zacks

4 months ago

Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates

AKBA

Associated Press Finance

4 months ago

Akebia Therapeutics: Q3 Earnings Snapshot

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
AKBA

PR Newswire

4 months ago

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AKBA

PR Newswire

4 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights
AKBA

PR Newswire

4 months ago

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights

High Growth Tech Stocks to Watch in October 2024
AKBA

Simply Wall St.

4 months ago

High Growth Tech Stocks to Watch in October 2024

AKBA

MT Newswires

4 months ago

Akebia Therapeutics Signs Contract to Expand Vafseo Access for Patients on Dialysis; Shares Rise

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
AKBA

PR Newswire

4 months ago

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024
AKBA

PR Newswire

4 months ago

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024

AKBA

MT Newswires

4 months ago

Akebia Therapeutics Says Vafseo Granted TDAPA Reimbursement

CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025
AKBA

PR Newswire

4 months ago

CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025

Akebia Therapeutics Inc (AKBA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...
AKBA

GuruFocus.com

4 months ago

Akebia Therapeutics Inc (AKBA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...

AKBA

MT Newswires

5 months ago

Akebia Therapeutics Enters Multi-Year Supply Contract With U.S. Renal Care for Vafseo

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
AKBA

PR Newswire

5 months ago

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Path To Profitability
AKBA

Simply Wall St.

5 months ago

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Path To Profitability

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AKBA

PR Newswire

5 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis
AKBA

PR Newswire

6 months ago

Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AKBA

PR Newswire

6 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
AKBA

Zacks

6 months ago

Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?

Here's Why You Should Consider Buying Akebia (AKBA) Stock
AKBA

Zacks

6 months ago

Here's Why You Should Consider Buying Akebia (AKBA) Stock

Akebia Therapeutics to Present at Upcoming Investor Conferences
AKBA

PR Newswire

6 months ago

Akebia Therapeutics to Present at Upcoming Investor Conferences

Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia
AKBA

Zacks

6 months ago

Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia

5 Small Drug Stocks to Buy as Innovation Reaches Peak
AKBA

Zacks

6 months ago

5 Small Drug Stocks to Buy as Innovation Reaches Peak

Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year?
AKBA

Zacks

6 months ago

Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Just Reported And Analysts Have Been Lifting Their Price Targets
AKBA

Simply Wall St.

6 months ago

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Just Reported And Analysts Have Been Lifting Their Price Targets

Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
AKBA

Zacks

6 months ago

Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates

AKBA

Associated Press Finance

6 months ago

Akebia Therapeutics: Q2 Earnings Snapshot

Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
AKBA

PR Newswire

6 months ago

Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights
AKBA

PR Newswire

7 months ago

Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AKBA

PR Newswire

7 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics to Present at Upcoming Investor Conferences
AKBA

PR Newswire

7 months ago

Akebia Therapeutics to Present at Upcoming Investor Conferences

AKBA

MT Newswires

7 months ago

Akebia Regains Full Rights to Sell Vafseo Tablets in US After Ending Licensing Deal With CSL Vifor

Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets
AKBA

PR Newswire

7 months ago

Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AKBA

PR Newswire

8 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
AKBA

PR Newswire

8 months ago

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

AKBA

MT Newswires

8 months ago

Akebia Therapeutics Names Erik Ostrowski CFO, CBO

Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer
AKBA

PR Newswire

8 months ago

Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer

Further weakness as Akebia Therapeutics (NASDAQ:AKBA) drops 16% this week, taking five-year losses to 80%
AKBA

Simply Wall St.

8 months ago

Further weakness as Akebia Therapeutics (NASDAQ:AKBA) drops 16% this week, taking five-year losses to 80%

Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge
AKBA

ACCESSWIRE

8 months ago

Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge

Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies
AKBA

Business Insider

8 months ago

Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
AKBA

GlobeNewswire

8 months ago

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger
AKBA

Motley Fool

8 months ago

Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger

Unifor members vote to strike at Manitoba Hydro
AKBA

CNW Group

8 months ago

Unifor members vote to strike at Manitoba Hydro

Croatia beat Portugal in Euro 2024 warm-up friendly
AKBA

AFP

8 months ago

Croatia beat Portugal in Euro 2024 warm-up friendly

Mark Cuban explains how he helped turn 300 of his employees into millionaires
AKBA

Business Insider

8 months ago

Mark Cuban explains how he helped turn 300 of his employees into millionaires

Here's what to do if you missed out on the massive 54% stock market rally since October 2022
AKBA

Business Insider

8 months ago

Here's what to do if you missed out on the massive 54% stock market rally since October 2022

[Latest] Global Virtual Reality In Gaming Market Size/Share Worth USD 103,244.7 Million by 2033 at a 16.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
AKBA

GlobeNewswire

9 months ago

[Latest] Global Virtual Reality In Gaming Market Size/Share Worth USD 103,244.7 Million by 2033 at a 16.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

AKBA

Business Wire

9 months ago

Net Asset Value(s)

CCF Group Successful €225m AT1 Issuance
AKBA

Business Wire

9 months ago

CCF Group Successful €225m AT1 Issuance

Should You Hold 908 Devices (MASS)?
AKBA

Insider Monkey

9 months ago

Should You Hold 908 Devices (MASS)?

Bangladesh Ecommerce Market Report 2024, Featuring Daraz Bangladesh, Chaldal, Evaly, Pickaboo and Ajkerdeal - Forecasts to 2028
AKBA

GlobeNewswire

9 months ago

Bangladesh Ecommerce Market Report 2024, Featuring Daraz Bangladesh, Chaldal, Evaly, Pickaboo and Ajkerdeal - Forecasts to 2028

3 Major Product Releases at 3Shape Discover Event
AKBA

PR Newswire

9 months ago

3 Major Product Releases at 3Shape Discover Event

Calculating The Fair Value Of Mincon Group plc (LON:MCON)
AKBA

Simply Wall St.

9 months ago

Calculating The Fair Value Of Mincon Group plc (LON:MCON)

Flash News: OKX Launches 'Trade and Earn' Campaign Featuring 2,500,000 Ultiverse Tokens
AKBA

GlobeNewswire

9 months ago

Flash News: OKX Launches 'Trade and Earn' Campaign Featuring 2,500,000 Ultiverse Tokens

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AKBA

PR Newswire

9 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference
AKBA

PR Newswire

9 months ago

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference

Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference
AKBA

PR Newswire

9 months ago

Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference

Revenue Downgrade: Here's What Analysts Forecast For Akebia Therapeutics, Inc. (NASDAQ:AKBA)
AKBA

Simply Wall St.

9 months ago

Revenue Downgrade: Here's What Analysts Forecast For Akebia Therapeutics, Inc. (NASDAQ:AKBA)

Akebia Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview
AKBA

GuruFocus.com

9 months ago

Akebia Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript
AKBA

Insider Monkey

9 months ago

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript

Akebia Therapeutics First Quarter 2024 Earnings: Misses Expectations
AKBA

Simply Wall St.

9 months ago

Akebia Therapeutics First Quarter 2024 Earnings: Misses Expectations

Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
AKBA

Zacks

9 months ago

Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates

AKBA

Associated Press Finance

9 months ago

Akebia Therapeutics: Q1 Earnings Snapshot

Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
AKBA

PR Newswire

9 months ago

Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
AKBA

PR Newswire

10 months ago

Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AKBA

PR Newswire

10 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?
AKBA

Simply Wall St.

10 months ago

When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AKBA

PR Newswire

a year ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia
AKBA

Benzinga

a year ago

FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia

Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
AKBA

Zacks

a year ago

Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD

Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
AKBA

PR Newswire

a year ago

Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis

Akebia Awaits FDA Word On Second Crack At Vadadustat
AKBA

Barrons.com

a year ago

Akebia Awaits FDA Word On Second Crack At Vadadustat

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.33
AKBA

Simply Wall St.

a year ago

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.33

Akebia Therapeutics Full Year 2023 Earnings: EPS Beats Expectations
AKBA

Simply Wall St.

a year ago

Akebia Therapeutics Full Year 2023 Earnings: EPS Beats Expectations

Akebia Therapeutics Inc (AKBA) Reports Steady Revenue and a Profitable Quarter
AKBA

GuruFocus.com

a year ago

Akebia Therapeutics Inc (AKBA) Reports Steady Revenue and a Profitable Quarter

Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
AKBA

Zacks

a year ago

Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4

Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
AKBA

PR Newswire

a year ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
AKBA

PR Newswire

a year ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AKBA

PR Newswire

a year ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AKBA

PR Newswire

a year ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Secures $55 Million Term Loan Financing
AKBA

PR Newswire

a year ago

Akebia Secures $55 Million Term Loan Financing

Tortoise Announces 2023 Closed-End Fund Tax Characterization of Distributions and Release of Combined Annual Report
AKBA

ACCESSWIRE

a year ago

Tortoise Announces 2023 Closed-End Fund Tax Characterization of Distributions and Release of Combined Annual Report

Bartesian Leverages Strategic Partnership with iHeartMedia to Drive Expansion in 2024
AKBA

PR Newswire

a year ago

Bartesian Leverages Strategic Partnership with iHeartMedia to Drive Expansion in 2024

Share on Social Networks: